Home Strains Research Conditions Breeders Compare Explorer Blog

Command Palette

Search for a command to run...

The world's most comprehensive cannabis strain directory, backed by scientific research.

Explore

Strain Directory Indica Strains Sativa Strains Hybrid Strains Breeders

Research

Research Database Medical Conditions Pain Relief Anxiety Insomnia

Tools

Strain Comparator Strain Explorer Blog API

© 2026 BudProfiles. For informational and educational purposes only.

Privacy Policy Terms of Service Disclaimer

11,121 strains · 12,304 studies · 268 breeders

Best Cannabis Strains for Systemic Sclerosis — 0 Strains, 0 Studies | BudProfiles

Home

Conditions

Systemic Sclerosis

Cannabis & Systemic Sclerosis

Explore 0 strains and 0 scientific studies related to Systemic Sclerosis.

0

Strains

0

Studies

18

Positive Studies

92%

Evidence Score

Research Evidence

18

Positive (90.0%)

1

Negative (5.0%)

1

Inconclusive (5.0%)

Scientific Studies

A Case of Panic Attacks Developing After 10 Years of Chronic Cannabis Use in a Patient With No Prior Psychiatric History

2023·Review/Other

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

2023·Clinical Trial

Cannabinoids for the Treatment of Dermatologic Conditions

2022·Review/Other

Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum

2021·Laboratory Study -

From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis

2021·Review/Other

Cannabis and the skin

2021·Review/Other

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis

2020·Clinical Trial

Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis

2019·Review/Other

VCE‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐ and CB2 receptor‐dependent pathways

2019·Review/Other

Cannabis sativa as a Potential Treatment for Systemic Sclerosis

2019·Review/Other

EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis

2018·Review/Other

Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation

2018·Review/Other

Cannabinoids in dermatology: a scoping review.

2018·Review/Other

The Therapeutic Potential of Cannabinoids in Dermatology

2018·Review/Other

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways.

2016·Review/Other

A CB2-Selective Cannabinoid Suppresses T-cell Activities and Increases Tregs and IL-10

2016·Review/Other

Effects of Cannabinoids on T-cell Function and Resistance to Infection.

2015·Review/Other

Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system.

2012·Review/Other

Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1

2012·Review/Other

Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis.

2012·Review/Other